Beijing Hotgen Biotech Co., Ltd. (688068)

Overview

Beijing Hotgen Biotech Co., Ltd. was established in 2005 and operates out of its headquarters based in Beijing, China. The company is a significant player in the biomedicine sector, concentrating on the research, development, manufacture, and sales of in-vitro diagnostic products. Their offerings are designed to cater to medical and public safety inspection markets, focusing on a broad spectrum of infectious diseases and safety concerns. With its dedication to innovation in biotechnology, Beijing Hotgen Biotech aims to contribute to global health and safety through its extensive product portfolio.

Products and Services

Beijing Hotgen Biotech Co., Ltd. provides an array of diagnostic products and technologies targeting various medical and safety applications:

• Drug Detection: Tools and kits designed for the rapid and accurate detection of illegal and prescription drugs within biological samples, offering solutions for law enforcement and medical monitoring.
• CDC (Centers for Disease Control and Prevention): Products supportive of public health initiatives, including tools for the detection and study of diseases that impact community health.
• Up-Conversion Luminescence Technology: A cutting-edge method employed in diagnostics for its high sensitivity and specificity, ideal for detecting low-abundance biomarkers in various diseases.
• Colloidal Gold: A quick and straightforward diagnostic tool utilizing colloidal gold particles, commonly employed in lateral flow assays for the detection of pathogens and proteins.
• CLIA (Chemiluminescence Immunoassay): High-sensitivity techniques used for the quantitative analysis of antigens and antibodies in various infectious disease tests.
• Sugar Capture: A novel technique aimed at capturing specific disease markers, enhancing the detection and analysis of certain conditions.
• Microfluidic: Miniaturized lab-on-a-chip devices that integrate several laboratory functions on a single chip, making diagnostics faster, more efficient, and requiring less sample volume.
• Gene Detection: Technologies and products for the identification and analysis of genes related to specific diseases, enabling personalized medicine and targeted treatments.
• Intestinal Microorganisms Testing: Diagnostic solutions focused on analyzing the gut microbiome to understand its relation to health and disease better.
• Gastrointestinal Foodborne Infections: Rapid testing kits designed to identify pathogens responsible for foodborne illnesses, improving food safety and public health.
• Insect-Borne Diseases: Diagnostic tools for the detection of diseases transmitted by insects, such as malaria or Zika virus, aiding in prevention and control efforts.
• Respiratory Pathogens: Tests and devices aimed at identifying pathogens that cause respiratory infections, critical for managing outbreaks of diseases such as influenza or COVID-19.
• Infectious Diseases: A broad category of products designed to diagnose a wide range of infectious diseases, supporting healthcare providers in effective disease management.
• Ebola Virus Antigen: Specific diagnostic products aimed at the rapid detection of the Ebola virus, crucial for outbreak response and containment.
• Biological Warfare Agents: Detection kits for identifying potential biological warfare agents, contributing to national defense and global security.
• Microorganisms: Broad-ranging solutions for the identification and quantification of microorganisms, applicable in medical, environmental, and industrial settings.
• Mycotoxins: Diagnostic tests for the detection of mycotoxins, toxic compounds produced by fungi, important for ensuring food safety and public health.